18.75
price down icon2.14%   -0.41
after-market 시간 외 거래: 19.51 0.76 +4.05%
loading
전일 마감가:
$19.16
열려 있는:
$19.06
하루 거래량:
3.88M
Relative Volume:
1.02
시가총액:
$13.93B
수익:
$220.00K
순이익/손실:
$-746.08M
주가수익비율:
-18.61
EPS:
-1.0074
순현금흐름:
$-211.81M
1주 성능:
-14.66%
1개월 성능:
-2.09%
6개월 성능:
-43.58%
1년 성능:
-6.39%
1일 변동 폭
Value
$18.46
$19.20
1주일 범위
Value
$18.08
$22.34
52주 변동 폭
Value
$15.55
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
명칭
Summit Therapeutics Inc
Name
전화
305-203-2034
Name
주소
601 BRICKELL KEY DRIVE, MIAMI
Name
직원
159
Name
트위터
@summitplc
Name
다음 수익 날짜
2025-10-20
Name
최신 SEC 제출 서류
Name
SMMT's Discussions on Twitter

SMMT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SMMT
Summit Therapeutics Inc
18.75 13.95B 220.00K -746.08M -211.81M -1.0074
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.63 109.29B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.00 62.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
575.69 61.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.18 51.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.03 34.68B 4.56B -176.77M 225.30M -1.7177

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-09-17 개시 Barclays Underweight
2025-09-04 개시 Guggenheim Buy
2025-08-19 개시 Piper Sandler Neutral
2025-07-01 개시 UBS Buy
2025-06-11 개시 Leerink Partners Underperform
2025-03-26 업그레이드 Citigroup Neutral → Buy
2025-03-21 개시 Cantor Fitzgerald Overweight
2025-03-12 개시 Evercore ISI Outperform
2025-02-28 개시 Goldman Buy
2025-01-08 개시 Truist Buy
2024-12-11 개시 Wells Fargo Overweight
2024-12-06 개시 Jefferies Buy
2024-11-04 개시 JMP Securities Mkt Outperform
2024-09-27 다운그레이드 Citigroup Buy → Neutral
2024-08-12 개시 H.C. Wainwright Buy
2024-05-07 개시 Citigroup Buy
2024-03-26 개시 Stifel Buy
2018-06-28 다운그레이드 Janney Buy → Neutral
2018-05-02 개시 Janney Buy
2018-04-12 재확인 Needham Buy
2018-02-13 개시 BTIG Research Buy
2018-01-04 개시 SunTrust Buy
2017-12-01 재개 H.C. Wainwright Buy
2016-11-16 재확인 RBC Capital Mkts Outperform
2016-10-05 재확인 Needham Buy
2016-09-16 개시 H.C. Wainwright Buy
2015-03-30 개시 Needham Buy
2015-03-30 개시 Oppenheimer Outperform
모두보기

Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스

pulisher
01:33 AM

Biotech Alert: Searches spiking for these stocks today - TipRanks

01:33 AM
pulisher
09:00 AM

Applying sector rotation models to Summit Therapeutics Inc.Market Trend Report & High Win Rate Trade Alerts - newser.com

09:00 AM
pulisher
08:07 AM

Is Summit Therapeutics Inc. showing signs of accumulationQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com

08:07 AM
pulisher
07:29 AM

Analyzing Summit Therapeutics Inc. with risk reward ratio chartsPortfolio Performance Report & AI Forecasted Entry/Exit Points - newser.com

07:29 AM
pulisher
05:35 AM

Summit Therapeutics raises $500 million - The Pharma Letter

05:35 AM
pulisher
04:51 AM

News impact scoring models applied to Summit Therapeutics Inc.Volume Spike & Safe Capital Growth Tips - newser.com

04:51 AM
pulisher
02:11 AM

Can Summit Therapeutics Inc. hit a new high this monthEarnings Performance Report & Risk Controlled Stock Pick Alerts - newser.com

02:11 AM
pulisher
02:09 AM

Should you hold or exit Summit Therapeutics Inc. nowTrade Exit Summary & Expert Curated Trade Ideas - newser.com

02:09 AM
pulisher
12:56 PM

Is Summit Therapeutics Inc. stock reversal real or fakeJuly 2025 Trends & Real-Time Chart Breakout Alerts - newser.com

12:56 PM
pulisher
Oct 22, 2025

Summit Therapeutics raises $500M in private placement - MSN

Oct 22, 2025
pulisher
Oct 22, 2025

Guggenheim Reiterates Summit Therapeutics (SMMT) Buy Recommendation - Nasdaq

Oct 22, 2025
pulisher
Oct 22, 2025

Understanding the Setup: (SMMT) and Scalable Risk - news.stocktradersdaily.com

Oct 22, 2025
pulisher
Oct 22, 2025

Summit Therapeutics (SMMT) Rating Reaffirmed at "Buy" by Guggenh - GuruFocus

Oct 22, 2025
pulisher
Oct 22, 2025

Summit Therapeutics (SMMT) Secures $500M in Stock Placement - GuruFocus

Oct 22, 2025
pulisher
Oct 22, 2025

Summit Therapeutics Raises $500M in Private Placement - TipRanks

Oct 22, 2025
pulisher
Oct 22, 2025

Summit Therapeutics raises $500 million in private placement - MarketScreener

Oct 22, 2025
pulisher
Oct 22, 2025

Summit Therapeutics Raises $500 Million in Private Placement - Business Wire

Oct 22, 2025
pulisher
Oct 21, 2025

Assessing Summit Therapeutics After Volatile Price Moves and Late-Stage Clinical Updates in 2025 - Yahoo Finance

Oct 21, 2025
pulisher
Oct 21, 2025

Summit Therapeutics Inc. stock momentum explainedWeekly Profit Report & Expert Curated Trade Setup Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Barclays Maintains Summit Therapeutics (SMMT) Underweight Recommendation - Nasdaq

Oct 21, 2025
pulisher
Oct 21, 2025

SA analyst upgrades/downgrades: TSLA, MSFT, AAPL, SMMT - Seeking Alpha

Oct 21, 2025
pulisher
Oct 21, 2025

SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments - TradingView

Oct 21, 2025
pulisher
Oct 21, 2025

SMMT: Barclays Raises Price Target to $16 While Maintaining "Und - GuruFocus

Oct 21, 2025
pulisher
Oct 21, 2025

HC Wainwright & Co. Maintains Summit Therapeutics (SMMT) Buy Recommendation - Nasdaq

Oct 21, 2025
pulisher
Oct 21, 2025

SMMT: HC Wainwright & Co. Lowers Price Target but Maintains Buy - GuruFocus

Oct 21, 2025
pulisher
Oct 21, 2025

Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - Insider Monkey

Oct 21, 2025
pulisher
Oct 21, 2025

13 Best Growth Stocks Under $25 to Buy Right Now - Insider Monkey

Oct 21, 2025
pulisher
Oct 21, 2025

Summit to seek US approval for ivonescimab in lung cancer despite survival miss - The Pharma Letter

Oct 21, 2025
pulisher
Oct 21, 2025

Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight - GuruFocus

Oct 21, 2025
pulisher
Oct 20, 2025

Summit Therapeutics Advances Ivonescimab Development Amid Financial Growth - TipRanks

Oct 20, 2025
pulisher
Oct 20, 2025

How to use Fibonacci retracement on Summit Therapeutics Inc.Quarterly Investment Review & Long-Term Safe Return Strategies - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Automated trading signals detected on Summit Therapeutics Inc.Trade Volume Report & Weekly Stock Breakout Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ... By GuruFocus - Investing.com Canada

Oct 20, 2025
pulisher
Oct 20, 2025

Citigroup Maintains Summit Therapeutics (SMMT) Buy Recommendation - Nasdaq

Oct 20, 2025
pulisher
Oct 20, 2025

Earnings call transcript: Summit Therapeutics Q3 2025 reports narrower loss, stock drops - Investing.com Nigeria

Oct 20, 2025
pulisher
Oct 20, 2025

Summit Therapeutics stock price target lowered to $42 by Jefferies - Investing.com Canada

Oct 20, 2025
pulisher
Oct 20, 2025

Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ... - Yahoo Finance

Oct 20, 2025
pulisher
Oct 20, 2025

Summit Therapeutics Launches New Phase III Study - TipRanks

Oct 20, 2025
pulisher
Oct 20, 2025

Summit’s Bold BLA Without Stat-Sig OS: Why I Step Back To Hold (NASDAQ:SMMT) - Seeking Alpha

Oct 20, 2025
pulisher
Oct 20, 2025

Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

JMP Securities Reiterates Summit Therapeutics (SMMT) Market Outperform Recommendation - Nasdaq

Oct 20, 2025
pulisher
Oct 20, 2025

Summit Seeks Cancer Drug’s Approval Despite US Regulator Warning - Bloomberg.com

Oct 20, 2025
pulisher
Oct 20, 2025

Summit Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat

Oct 20, 2025
pulisher
Oct 20, 2025

Citigroup Raises Price Target for Summit Therapeutics (SMMT) to $40 | SMMT Stock News - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

Summit Therapeutics (SMMT) Shares Dip on Q3 Earnings Miss - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

Is it time to cut losses on Summit Therapeutics Inc.Treasury Yields & Daily Chart Pattern Signal Reports - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

SMMT: JMP Securities Reiterates "Market Outperform" Rating Today | SMMT Stock News - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

Earnings call transcript: Summit Therapeutics Q3 2025 reports narrower loss, stock drops By Investing.com - Investing.com South Africa

Oct 20, 2025
pulisher
Oct 20, 2025

Summit Therapeutics Q3 2025 slides: positive HARMONI-6 data fails to lift stock - Investing.com

Oct 20, 2025
pulisher
Oct 20, 2025

What's Going On With Summit Therapeutics Stock On Monday? - Benzinga

Oct 20, 2025
pulisher
Oct 20, 2025

Summit Therapeutics stock rating reiterated by Cantor Fitzgerald By Investing.com - Investing.com South Africa

Oct 20, 2025

Summit Therapeutics Inc (SMMT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Summit Therapeutics Inc 주식 (SMMT) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Zanganeh Mahkam
Co-Chief Executive Officer
Sep 11 '25
Buy
18.07
5,000
90,350
556,093,090
DUGGAN ROBERT W
Co-Chief Executive Officer
Sep 10 '25
Buy
17.68
333,394
5,894,406
556,088,090
DUGGAN ROBERT W
Co-Chief Executive Officer
Sep 11 '25
Buy
18.07
5,000
90,350
556,093,090
Zanganeh Mahkam
Co-Chief Executive Officer
May 30 '25
Option Exercise
2.64
74,545
196,799
555,754,696
DUGGAN ROBERT W
Co-Chief Executive Officer
May 30 '25
Option Exercise
2.64
74,545
196,799
555,754,696
$36.85
price up icon 0.03%
$89.31
price up icon 1.42%
$29.87
price down icon 0.17%
$104.75
price down icon 1.39%
$160.11
price down icon 0.18%
biotechnology ONC
$310.03
price down icon 1.12%
자본화:     |  볼륨(24시간):